Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Lung Cancer Risk Prediction Model

February 25th 2013

Using different selection criteria for screening is superior to currently recommended criteria.

The Cost-Effectiveness of Targeted Therapies in NSCLC

February 13th 2013

Impact of EGFR Mutations on Treatment Decisions in NSCLC

February 13th 2013

Access to Molecular Testing Therapy in NSCLC

February 13th 2013

Personalizing the Treatment of Lung Cancer

February 13th 2013

Promising Emerging Classes of Therapies in NSCLC

February 13th 2013

Molecular Heterogeneity in Non-Small Cell Lung Cancer

February 13th 2013

Selecting Treatment for First- Line Non-Squamous NSCLC

February 13th 2013

Selecting a Laboratory for Molecular Testing in NSCLC

February 13th 2013

Rebiopsying and Molecular Testing in NSCLC

February 13th 2013

Molecular Testing and Actionable Targets in NSCLC

February 13th 2013

Best Practices in NSCLC Molecular Testing, Part II

February 13th 2013

Concurrent Versus Sequential Testing in NSCLC

February 13th 2013

Best Practices in NSCLC Molecular Testing, Part I

February 13th 2013

Introduction: Advances and Issues in NSCLC

February 13th 2013

Squamous Cell Carcinoma Treatment Options

February 13th 2013

Biotech Focus: Tracking the Oncology Pipeline

February 13th 2013

Several updates highlighted at the 2012 American Society of Hematology Annual Meeting as well as other developments.

Targeting Tumors Early: Trials Push Novel Agents to Forefront

February 11th 2013

New discoveries about tumor biology suggest to many researchers that targeted therapies, when used in appropriate early-stage patients, might significantly boost cure rates and extend lives.

BATTLE-2: Next-Generation of Biomarker-Driven Trials

February 8th 2013

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

Innovative BATTLE Trials Pair Agents, Biomarkers in NSCLC

February 7th 2013

As therapy based on cell-signaling pathways has become a priority in cancer research, so has the concept of designing clinical trials that can better target patient populations more likely to benefit from a particular regimen.